IL96449A - Medicinal product for administration via iontophoresis containing 1-Azacycloheptan-2-On or Zis-Ulpin as skin-enhancing fluxes - Google Patents

Medicinal product for administration via iontophoresis containing 1-Azacycloheptan-2-On or Zis-Ulpin as skin-enhancing fluxes

Info

Publication number: IL96449A
Authority: IL; Israel
Prior art keywords: cis; acid; composition according; formula; compound
Prior art date: 1989-11-29

Application number

IL9644990A

Other languages

English (en)

Hebrew (he)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-29

Filing date

1990-11-22

Publication date

1996-07-23

1990-11-22 Application filed by Pfizer filed Critical Pfizer

1996-07-23 Publication of IL96449A publication Critical patent/IL96449A/en

Links

230000004907 flux Effects 0.000 title claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
239000003623 enhancer Substances 0.000 title abstract description 7
239000008177 pharmaceutical agent Substances 0.000 claims abstract description 31
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 18
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 18
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 16
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 14
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 14
239000005642 Oleic acid Substances 0.000 claims abstract description 14
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 14
238000011200 topical administration Methods 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims description 24
235000021313 oleic acid Nutrition 0.000 claims description 17
150000001875 compounds Chemical class 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
239000003961 penetration enhancing agent Substances 0.000 claims description 7
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 6
231100000223 dermal penetration Toxicity 0.000 claims description 6
229960001389 doxazosin Drugs 0.000 claims description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
229960002702 piroxicam Drugs 0.000 claims description 6
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 6
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
239000003125 aqueous solvent Substances 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 4
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
239000004100 Oxytetracycline Substances 0.000 claims description 3
229930195708 Penicillin V Natural products 0.000 claims description 3
239000004098 Tetracycline Substances 0.000 claims description 3
229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
229960003022 amoxicillin Drugs 0.000 claims description 3
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
229960000723 ampicillin Drugs 0.000 claims description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
239000000730 antalgic agent Substances 0.000 claims description 3
229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
239000002260 anti-inflammatory agent Substances 0.000 claims description 3
229940121375 antifungal agent Drugs 0.000 claims description 3
229960004099 azithromycin Drugs 0.000 claims description 3
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 3
201000010099 disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
229960003722 doxycycline Drugs 0.000 claims description 3
229960003276 erythromycin Drugs 0.000 claims description 3
229960004884 fluconazole Drugs 0.000 claims description 3
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical group C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 3
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 3
229960001381 glipizide Drugs 0.000 claims description 3
229960001680 ibuprofen Drugs 0.000 claims description 3
229960000905 indomethacin Drugs 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
229960002009 naproxen Drugs 0.000 claims description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
229960001597 nifedipine Drugs 0.000 claims description 3
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
229960000625 oxytetracycline Drugs 0.000 claims description 3
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 3
235000019366 oxytetracycline Nutrition 0.000 claims description 3
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
229960005489 paracetamol Drugs 0.000 claims description 3
229940056367 penicillin v Drugs 0.000 claims description 3
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 3
229960001289 prazosin Drugs 0.000 claims description 3
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 3
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 3
229960002073 sertraline Drugs 0.000 claims description 3
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 3
229960002180 tetracycline Drugs 0.000 claims description 3
235000019364 tetracycline Nutrition 0.000 claims description 3
229930101283 tetracycline Natural products 0.000 claims description 3
150000003522 tetracyclines Chemical class 0.000 claims description 3
229960004214 tioconazole Drugs 0.000 claims description 3
OXEDXHIBHVMDST-SREVYHEPSA-N (z)-octadec-12-enoic acid Chemical compound CCCCC\C=C/CCCCCCCCCCC(O)=O OXEDXHIBHVMDST-SREVYHEPSA-N 0.000 claims description 2
VQDOIVGYJXZOQY-KTKRTIGZSA-N (z)-pentadec-6-enoic acid Chemical compound CCCCCCCC\C=C/CCCCC(O)=O VQDOIVGYJXZOQY-KTKRTIGZSA-N 0.000 claims description 2
RMUJWENALAQPCS-SREVYHEPSA-N 14(Z)-eicosenoic acid Chemical compound CCCCC\C=C/CCCCCCCCCCCCC(O)=O RMUJWENALAQPCS-SREVYHEPSA-N 0.000 claims description 2
FPAQLJHSZVFKES-NXVVXOECSA-N 5Z-eicosenoic acid Chemical compound CCCCCCCCCCCCCC\C=C/CCCC(O)=O FPAQLJHSZVFKES-NXVVXOECSA-N 0.000 claims description 2
NNNVXFKZMRGJPM-UHFFFAOYSA-N 6-Hexadecenoic acid Natural products CCCCCCCCCC=CCCCCC(O)=O NNNVXFKZMRGJPM-UHFFFAOYSA-N 0.000 claims description 2
YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
101100295741 Gallus gallus COR4 gene Chemical group 0.000 claims description 2
CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 claims description 2
230000000202 analgesic effect Effects 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
239000003429 antifungal agent Substances 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
229940108623 eicosenoic acid Drugs 0.000 claims description 2
LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 claims description 2
YWWVWXASSLXJHU-WAYWQWQTSA-N myristoleic acid Chemical group CCCC\C=C/CCCCCCCC(O)=O YWWVWXASSLXJHU-WAYWQWQTSA-N 0.000 claims description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims description 2
229940056360 penicillin g Drugs 0.000 claims description 2
CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 claims description 2
229940002612 prodrug Drugs 0.000 claims description 2
239000000651 prodrug Substances 0.000 claims description 2
NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims description 2
XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims 1
PCEPYENXHJPCEF-UHFFFAOYSA-N 1-decylazepan-2-one Chemical compound CCCCCCCCCCN1CCCCCC1=O PCEPYENXHJPCEF-UHFFFAOYSA-N 0.000 claims 1
NDFFLUPUGUDAOM-UHFFFAOYSA-N 1-tetradecylazepan-2-one Chemical compound CCCCCCCCCCCCCCN1CCCCCC1=O NDFFLUPUGUDAOM-UHFFFAOYSA-N 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract 1
229940079593 drug Drugs 0.000 description 19
239000000243 solution Substances 0.000 description 15
238000000034 method Methods 0.000 description 13
210000001519 tissue Anatomy 0.000 description 12
238000012385 systemic delivery Methods 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000002500 effect on skin Effects 0.000 description 7
239000000872 buffer Substances 0.000 description 6
230000006378 damage Effects 0.000 description 6
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
229910001415 sodium ion Inorganic materials 0.000 description 5
208000002193 Pain Diseases 0.000 description 4
229910021607 Silver chloride Inorganic materials 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000000700 radioactive tracer Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
-1 Na+ Chemical class 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241000764773 Inna Species 0.000 description 1
206010024774 Localised infection Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000005331 crown glasses (windows) Substances 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000003780 hair follicle Anatomy 0.000 description 1
238000005286 illumination Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
229960003676 tenidap Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL9644990A 1989-11-29 1990-11-22 Medicinal product for administration via iontophoresis containing 1-Azacycloheptan-2-On or Zis-Ulpin as skin-enhancing fluxes IL96449A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/443,699 US5023085A (en)	1989-11-29	1989-11-29	Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals

Publications (1)

Publication Number	Publication Date
IL96449A true IL96449A (en)	1996-07-23

Family

ID=23761854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9644990A IL96449A (en)	1989-11-29	1990-11-22	Medicinal product for administration via iontophoresis containing 1-Azacycloheptan-2-On or Zis-Ulpin as skin-enhancing fluxes

Country Status (17)

Country	Link
US (1)	US5023085A (de)
EP (1)	EP0435436B1 (de)
JP (1)	JPH0688912B2 (de)
KR (1)	KR930007248B1 (de)
AT (1)	ATE99961T1 (de)
AU (1)	AU613281B1 (de)
CA (1)	CA2030943A1 (de)
DE (1)	DE69006000T2 (de)
DK (1)	DK0435436T3 (de)
HU (1)	HUT55629A (de)
IE (1)	IE63597B1 (de)
IL (1)	IL96449A (de)
MY (1)	MY109727A (de)
NZ (1)	NZ236253A (de)
PH (1)	PH27105A (de)
PT (1)	PT96021B (de)
ZA (1)	ZA909512B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5196410A (en) *	1986-10-31	1993-03-23	Pfizer Inc.	Transdermal flux enhancing compositions
DE3880923T3 (de) *	1987-02-23	1997-12-18	Shiseido Co Ltd	Perkutaner absorptionspromotor und dermatologische zusammensetzung für externe anwendung.
US5080646A (en) *	1988-10-03	1992-01-14	Alza Corporation	Membrane for electrotransport transdermal drug delivery
US5262165A (en) *	1992-02-04	1993-11-16	Schering Corporation	Transdermal nitroglycerin patch with penetration enhancers
US5302172A (en) *	1990-03-15	1994-04-12	North Carolina State University	Method and composition for iontophoresis
US5383848A (en) *	1990-04-12	1995-01-24	Gensia, Inc.	Iontophoretic administration of drugs
US6582416B2 (en)	1990-11-01	2003-06-24	Robert Tapper	Iontophoretic treatment system
US6139537A (en) *	1990-11-01	2000-10-31	Tapper; Robert	Iontophoretic treatment system
US6238381B1 (en)	1990-11-01	2001-05-29	Robert Tapper	Iontophoretic treatment system
US6223076B1 (en)	1990-11-01	2001-04-24	Robert Tapper	Sweat control system
US6235013B1 (en)	1990-11-01	2001-05-22	Robert Tapper	Iontophoretic treatment system
US5224927A (en) *	1990-11-01	1993-07-06	Robert Tapper	Iontophoretic treatment system
US6575957B1 (en) *	1990-11-01	2003-06-10	Robert Tapper	Iontophoretic treatment system
US6600950B1 (en) *	1990-11-01	2003-07-29	Robert Tapper	Iontophoretic treatment system
US5131403A (en) *	1991-06-05	1992-07-21	Becton Dickinson And Company	Method for obtaining blood using iontophoresis
US5356632A (en) *	1991-09-12	1994-10-18	S.I. Scientific Innovations Ltd.	Transdermal drug delivery device
EP0552879B1 (de) *	1992-01-21	1998-08-19	Macrochem Corporation	Iontophoretische verbesserte Verabreichung von Medikamenten
DE69407061T2 (de) *	1992-06-02	1998-06-04	Alza Corp., Palo Alto, Calif.	Abgabevorrichtung zur elektrischen übertragung von arzneimitteln
US5580574A (en) *	1994-04-28	1996-12-03	Hoffmann-La Roche Inc.	Pharmaceutical composition for transdermal delivery
US5594015A (en) *	1994-06-22	1997-01-14	Regents Of The University Of California	Thiazolidine derivatives for the treatment of psoriasis
JP4090072B2 (ja) *	1994-07-13	2008-05-28	アルザ・コーポレーション	経皮電気的移送式作用剤投与を促進するための組成物と方法
US5540654A (en) *	1994-09-02	1996-07-30	North Carolina State University	Iontophoretic electrode
US5736580A (en) *	1994-11-14	1998-04-07	Alza Croporation	Composition, device, and method for electrotransport agent delivery
US5861439A (en) *	1994-11-14	1999-01-19	Alza Corporation	Method for enhanced electrotransport agent delivery
US5985316A (en) *	1995-04-28	1999-11-16	Alza Corporation	Composition and method of enhancing electrotransport agent delivery
US5990179A (en) *	1995-04-28	1999-11-23	Alza Corporation	Composition and method of enhancing electrotransport agent delivery
US6355025B1 (en)	1995-06-07	2002-03-12	Alza Corporation	Adjustable electrotransport drug delivery using a fixed output controller
WO1997014473A1 (en) *	1995-10-18	1997-04-24	Novartis Ag	Thermopile powered transdermal drug delivery device
US7094422B2 (en)	1996-02-19	2006-08-22	Acrux Dds Pty Ltd.	Topical delivery of antifungal agents
AUPN814496A0 (en)	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
EP0849265A1 (de) *	1996-12-20	1998-06-24	HEUMANN PHARMA GmbH	Neue polymorphe Form von Doxazosin-Mesylat (Form II)
AUPO907697A0 (en) *	1997-09-09	1997-10-02	Day, Robert Edward	Chemical supplementation of bone
GB9723669D0 (en) *	1997-11-07	1998-01-07	Univ Aberdeen	Skin penetration enhancing components
AU766913B2 (en)	1998-11-02	2003-10-23	Alza Corporation	Electrotransport device including a compatible antimicrobial agent
JP2001072592A (ja)	1999-07-01	2001-03-21	Kyowa Hakko Kogyo Co Ltd	テロメラーゼ阻害剤
US6512950B2 (en)	2000-02-18	2003-01-28	University Of Utah Research Foundation	Methods for delivering agents using alternating current
CA2400074A1 (en)	2000-02-18	2001-08-23	William I. Higuchi	Methods for extracting substances using alternating current
US6452014B1 (en)	2000-12-22	2002-09-17	Geron Corporation	Telomerase inhibitors and methods of their use
US7137975B2 (en) *	2001-02-13	2006-11-21	Aciont, Inc.	Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
CA2443326A1 (en) *	2001-04-04	2002-10-17	Alza Corporation	Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
US7099713B2 (en)	2002-06-28	2006-08-29	Battelle Memorial Institute	Skin conduction and transport systems
US7468428B2 (en) *	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US20050220439A1 (en) *	2004-03-19	2005-10-06	Carton Owen A	Interactive multimedia system and method
US20060222692A1 (en) *	2005-03-31	2006-10-05	Fairfield Clinical Trials Llc	Method and compositions for transdermal administration of antimicrobial medications
US20080200533A1 (en) *	2005-07-04	2008-08-21	Ramu Krishnan	Drug or Pharmaceutical Compounds and a Preparation Thereof
WO2007147043A2 (en) *	2006-06-16	2007-12-21	Transport Pharmaceutical, Inc.	Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery
EP2363116A1 (de)	2008-06-25	2011-09-07	US Worldmeds LLC	Lofexidin enthaltende Formulierungen mit verzögerter Freisetzung zur oralen Verabreichung
WO2010054356A1 (en) *	2008-11-10	2010-05-14	Nitric Biotherapeutics, Inc.	Pharmaceutical formulations for iontophoretic delivery of a corticosteroid
US20100331812A1 (en) *	2009-06-29	2010-12-30	Nitric Biotherapeutics, Inc.	Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator
WO2011130455A1 (en)	2010-04-13	2011-10-20	Najib Babul	Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
HRP20220112T1 (hr)	2013-12-24	2022-04-15	Virginia Commonwealth University	Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
US11564970B2 (en)	2017-10-09	2023-01-31	The Broad Institute, Inc.	Compositions and methods for combinatorial drug discovery in nanoliter droplets

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3991755A (en) *	1973-07-27	1976-11-16	Medicon, Inc.	Iontophoresis apparatus for applying local anesthetics
US3989816A (en) *	1975-06-19	1976-11-02	Nelson Research & Development Company	Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) *	1975-06-19	1982-02-23	Nelson Research & Development Co.	Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) *	1975-06-19	1983-09-20	Nelson Research & Development Company	Penetration enhancers for transdermal drug delivery of systemic agents
US4954487A (en) *	1979-01-08	1990-09-04	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions
JPS6036299B2 (ja) *	1981-07-02	1985-08-20	タカラベルモント株式会社	イオン導入器
HU185691B (en) *	1982-02-09	1985-03-28	Richter Gedeon Vegyeszet	Process for preparing a new analgetic pharmaceutical composition
US4557934A (en) *	1983-06-21	1985-12-10	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4919648A (en) *	1983-08-18	1990-04-24	Drug Delivery Systems Inc.	High tack drug patch
JPS6222662A (ja) *	1985-07-19	1987-01-30	林原　健	イオン導入電子治療器
MY102980A (en) *	1986-10-31	1993-03-31	Pfizer	Transdermal flux enhancing compositions
US5108363A (en) *	1988-02-19	1992-04-28	Gensia Pharmaceuticals, Inc.	Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
ATE80313T1 (de) *	1988-02-29	1992-09-15	Pfizer	Mittel zur erhoehung des transdermalen penetrationsflusses.

1989
- 1989-11-29 US US07/443,699 patent/US5023085A/en not_active Expired - Fee Related
1990
- 1990-11-02 PH PH41182A patent/PH27105A/en unknown
- 1990-11-08 DE DE90312217T patent/DE69006000T2/de not_active Expired - Fee Related
- 1990-11-08 AT AT90312217T patent/ATE99961T1/de not_active IP Right Cessation
- 1990-11-08 DK DK90312217.4T patent/DK0435436T3/da active
- 1990-11-08 EP EP90312217A patent/EP0435436B1/de not_active Expired - Lifetime
- 1990-11-22 IL IL9644990A patent/IL96449A/en not_active IP Right Cessation
- 1990-11-27 ZA ZA909512A patent/ZA909512B/xx unknown
- 1990-11-27 MY MYPI90002098A patent/MY109727A/en unknown
- 1990-11-27 CA CA002030943A patent/CA2030943A1/en not_active Abandoned
- 1990-11-28 HU HU907681A patent/HUT55629A/hu unknown
- 1990-11-28 IE IE428190A patent/IE63597B1/en not_active IP Right Cessation
- 1990-11-28 PT PT96021A patent/PT96021B/pt not_active IP Right Cessation
- 1990-11-28 AU AU67069/90A patent/AU613281B1/en not_active Ceased
- 1990-11-28 NZ NZ236253A patent/NZ236253A/xx unknown
- 1990-11-28 KR KR1019900019334A patent/KR930007248B1/ko not_active Expired - Fee Related
- 1990-11-29 JP JP2333509A patent/JPH0688912B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MY109727A (en)	1997-05-31
NZ236253A (en)	1993-05-26
JPH03176426A (ja)	1991-07-31
IE904281A1 (en)	1991-06-05
PT96021B (pt)	1998-02-27
KR930007248B1 (ko)	1993-08-04
EP0435436A2 (de)	1991-07-03
ATE99961T1 (de)	1994-01-15
DK0435436T3 (da)	1994-02-28
EP0435436A3 (en)	1992-01-08
DE69006000D1 (de)	1994-02-24
ZA909512B (en)	1992-06-24
JPH0688912B2 (ja)	1994-11-09
CA2030943A1 (en)	1991-05-30
EP0435436B1 (de)	1994-01-12
PH27105A (en)	1993-03-16
PT96021A (pt)	1991-09-13
IE63597B1 (en)	1995-05-17
KR910009250A (ko)	1991-06-28
DE69006000T2 (de)	1994-05-05
HUT55629A (en)	1991-06-28
AU613281B1 (en)	1991-07-25
US5023085A (en)	1991-06-11

Legal Events

Date	Code	Title
1996-12-05	FF	Patent granted
1997-02-18	KB	Patent renewed
2001-07-24	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0435436B1 (de)	1994-01-12	Verstärker des transdermalen Flusses in Kombination mit Iontophorese für die topische Verabreichung von Arzneimitteln
Bellantone et al.	1986	Enhanced percutaneous absorption via iontophoresis I. Evaluation of an in vitro system and transport of model compounds
AU2006201898C1 (en)	2009-10-15	Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
Khan et al.	2011	Iontophoretic drug delivery: history and applications
DE69925105T2 (de)	2006-01-26	Iontophoretische vorrichtung enthaltend piperidinderivate
JPS63102768A (ja)	1988-05-07	イオントフオレ−シス用の新規プラスタ−構造体
NZ238804A (en)	1992-08-26	Transdermal composition of a weak base drug and a lysosomal uptake drug that reduces skin irritation
JPH11504229A (ja)	1999-04-20	電気的輸送薬剤分配を増進する組成物および方法
RU2166315C2 (ru)	2001-05-10	Ионтофоретическая доставка противомигреневого препарата
JP3874795B2 (ja)	2007-01-31	電気的移送式作用剤投与を促進する組成物
JP3261501B2 (ja)	2002-03-04	改善されたイオン導入法による薬剤投与方法
Sugibayashi et al.	1989	Utility of topical formulations of morphine hydrochloride containing azone and N-methyl-2-pyrrolidone
US20250360156A1 (en)	2025-11-27	Synergistic combination of nad+ and therapeutic peptides delivered via iontophoresis for enhanced and prolonged regenerative effects
Lelawongs	1990	Transdermal iontophoretic delivery of arginine vasopressin
Bhat et al.	0	Pharmacology & Pharmacotherapeutics
Lee et al.	1991	A Study on the Penetration of Dexamethasone into Oral Mucosa with the Use of Iontophoresis
Wang	1997	Transdermal delivery of cyclosporin A by electrically enhanced permeation techniques